| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2018 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 50,000 | $46.14 | $2,306,970.00 | +1.5% | |
| Aug 3, 2018 | MRK Merck & Co., Inc. | Chattopadhyay Sanat | Exe V-p &Pres. Mmd | Sell | 29,208 | $65.20 | $1,904,361.60 | -36.2% | |
| Aug 2, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 190,000 | $99.58 | $18,919,938.63 | - | |
| Aug 2, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 19,400 | $13.31 | $258,214.00 | -0.5% | |
| Aug 2, 2018 | MRK Merck & Co., Inc. | Karachun Rita A | Sr. VP Fince-global Controller | Sell | 5,000 | $65.01 | $325,040.00 | -23.6% | |
| Aug 2, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 4,702 | $3.33 | $15,657.66 | -0.2% | |
| Aug 1, 2018 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 23,022 | $110.00 | $2,532,420.00 | -21.7% | |
| Aug 1, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $43.68 | $43,680.00 | -100% | |
| Aug 1, 2018 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 28,266 | $115.00 | $3,250,590.00 | -26.4% | |
| Aug 1, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 12,681 | $3.17 | $40,157.82 | -0.3% | |
| Jul 31, 2018 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 228,091 | $65.00 | $14,826,690.51 | -24.3% | |
| Jul 31, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 205,000 | $98.74 | $20,240,872.93 | - | |
| Jul 30, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 8,458 | $3.35 | $28,368.04 | -0.2% | |
| Jul 27, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 12,000 | $47.35 | $568,200.00 | -15.4% | |
| Jul 27, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 12,000 | $47.35 | $568,200.00 | -15.4% | |
| Jul 26, 2018 | LLY Eli Lilly & Co | Tai Jackson P | Director | Buy | 2,168 | $95.22 | $206,436.96 | +4.2% | |
| Jul 26, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 20,397 | $3.76 | $76,657.71 | -0.4% | |
| Jul 25, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 190,000 | $94.73 | $17,999,258.93 | - | |
| Jul 24, 2018 | AQST Aquestive Therapeutics, Inc. | Bratton Douglas K | Director, 10% Owner | Buy | 165,000 | $15.00 | $2,475,000.00 | New | |
| Jul 24, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 185,000 | $92.03 | $17,025,984.90 | - | |
| Jul 24, 2018 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 31,300 | $4.25 | $132,927.00 | -0.6% | |
| Jul 23, 2018 | TLRY Tilray Brands, Inc. | Pastorius Edward Wood Jr | Chief Revenue Officer | Buy | 14,705 | $17.00 | $249,985.00 | New | |
| Jul 23, 2018 | TLRY Tilray Brands, Inc. | Castaneda Mark | CFO, Secretary, Treasurer | Buy | 14,705 | $17.00 | $249,985.00 | New | |
| Jul 23, 2018 | TLRY Tilray Brands, Inc. | Kennedy Brendan87 | President And CEO | Buy | 14,706 | $17.00 | $250,002.00 | New | |
| Jul 19, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack50 | President And CEO | Sell | 17,470 | $47.92 | $837,134.00 | -14.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.